10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis
10x Genomics (Nasdaq: TXG) has launched Xenium Protein, an innovative addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell and tissue section in a single automated run. This breakthrough represents the first fully integrated spatial multiomic workflow for the Xenium platform.
The new product features ready-to-use protein subpanels that work alongside RNA panels, including dozens of proteins involved in cell growth, signaling, and immune response. The technology streamlines research workflows by eliminating the need for separate technologies or sample sections, particularly beneficial for studying cancer, immunology, and complex diseases.
Early adoption by companies like Sanofi demonstrates the platform's value in providing comprehensive tissue architecture analysis and cell-cell interaction insights without complex data co-registration requirements.
10x Genomics (Nasdaq: TXG) ha lanciato Xenium Protein, un'aggiunta innovativa alla piattaforma Xenium Spatial che consente la rilevazione simultanea di RNA e proteine nella stessa cellula e nella medesima sezione di tessuto in un'unica corsa automatizzata. Questa novit脿 rappresenta il primo flusso di lavoro multiomico spaziale completamente integrato per la piattaforma Xenium.
Il prodotto offre sottopannelli proteici pronti all'uso che si affiancano ai pannelli per RNA, includendo decine di proteine coinvolte nella crescita cellulare, nella segnalazione e nella risposta immunitaria. La tecnologia semplifica i flussi di lavoro di ricerca eliminando la necessit脿 di tecnologie o sezioni di campione separate, particolarmente utile nello studio di tumori, immunologia e malattie complesse.
L'adozione precoce da parte di aziende come Sanofi dimostra il valore della piattaforma nel fornire un'analisi completa dell'architettura tissutale e delle interazioni cellula-cellula senza il bisogno di complessi processi di co-registrazione dei dati.
10x Genomics (Nasdaq: TXG) ha lanzado Xenium Protein, una incorporaci贸n innovadora a su plataforma Xenium Spatial que permite detectar simult谩neamente ARN y prote铆nas en la misma c茅lula y secci贸n de tejido en una 煤nica ejecuci贸n automatizada. Este avance representa el primer flujo de trabajo multi贸mico espacial totalmente integrado para la plataforma Xenium.
El nuevo producto incluye subpaneles proteicos listos para usar que complementan los paneles de ARN, con docenas de prote铆nas relacionadas con el crecimiento celular, la se帽alizaci贸n y la respuesta inmune. La tecnolog铆a optimiza los procesos de investigaci贸n al eliminar la necesidad de tecnolog铆as o secciones de muestra separadas, algo especialmente valioso para el estudio del c谩ncer, la inmunolog铆a y enfermedades complejas.
La adopci贸n temprana por parte de empresas como Sanofi muestra el valor de la plataforma para ofrecer un an谩lisis integral de la arquitectura tisular y de las interacciones c茅lula a c茅lula sin requisitos complejos de co-registro de datos.
10x Genomics (雮橃姢雼�: TXG)電� 霃欖澕頃� 靹疙彫鞕� 臁办 鞝堩幐鞐愳劀 RNA鞕� 雼氨歆堨潉 霃欖嫓鞐� 瓴�於滍暊 靾� 鞛堧姅 Xenium Spatial 頂岆灚韽检潣 順侅嫚鞝� 頇曥灔鞚� Xenium Protein鞚� 於滌嫓頄堨姷雼堧嫟. 鞚� 鞝滍拡鞚� 頃� 氩堨潣 鞛愲彊頇旊悳 鞁ろ枆鞙茧 鞚措（鞏挫電� Xenium 頂岆灚韽检毄 斓滌磮鞚� 鞕勳爠 韱淀暕 瓿店皠 雼れ鞓る鞀� 鞗岉伂頂岆鞖半ゼ 鞚橂頃╇媹雼�.
鞁犾牅頀堨潃 RNA 韺剱瓿� 頃粯 靷毄頃� 靾� 鞛堧姅 歃夓嫓 靷毄 臧�電ロ暅 雼氨歆� 靹滊笇韺剱鞚� 鞝滉车頃橂┌, 靹疙彫 靹膘灔, 鞁犿樃 鞝勲嫭 氚� 氅挫棴 氚橃潙鞐� 甏�鞐晿電� 靾橃嫮 膦呾潣 雼氨歆堨潉 韽暔頃╇媹雼�. 鞚� 旮办垹鞚� 氤勲弰鞚� 旮办垹鞚措倶 靸橅攲 鞝堩幐鞚� 頃勳殧 鞐嗠弰搿� 鞐瓣惮 鞗岉伂頂岆毳� 臧勳唽頇旐晿鞐� 鞎�, 氅挫棴頃� 氚� 氤奠灐頃� 歆堩櫂 鞐瓣惮鞐� 韸鬼瀳 鞙犾毄頃╇媹雼�.
Sanofi鞕� 臧欖潃 旮办梾鞚� 齑堦赴 霃勳瀰 靷電� 氤奠灐頃� 雿办澊韯� 瓿惦彊 鞝曧暕(co-registration) 瓿检爼鞚� 頃勳殧搿� 頃橃 鞎婌溂氅挫劀霃� 臁办 甑“ 攵勳劃瓿� 靹疙彫 臧� 靸來樃鞛戩毄鞐� 雽�頃� 韽磩鞝� 韱奠鞍鞚� 鞝滉车頃橂姅 頂岆灚韽检潣 臧�旃橂ゼ 鞛呾頃╇媹雼�.
10x Genomics (Nasdaq: TXG) a lanc茅 Xenium Protein, une nouveaut茅 de sa plateforme Xenium Spatial permettant la d茅tection simultan茅e d'ARN et de prot茅ines dans la m锚me cellule et la m锚me coupe de tissu lors d'un unique cycle automatis茅. Il s'agit du premier flux de travail multiomique spatial enti猫rement int茅gr茅 pour la plateforme Xenium.
Le produit propose des sous-panneaux prot茅iques pr锚ts 脿 l'emploi, compl茅mentaires des panneaux ARN, couvrant des dizaines de prot茅ines impliqu茅es dans la croissance cellulaire, la signalisation et la r茅ponse immunitaire. Cette technologie rationalise les protocoles de recherche en supprimant le recours 脿 des technologies ou 脿 des sections d'茅chantillon s茅par茅es, ce qui est particuli猫rement utile pour l'茅tude du cancer, de l'immunologie et des maladies complexes.
L'adoption pr茅coce par des soci茅t茅s telles que Sanofi illustre la valeur de la plateforme pour fournir une analyse compl猫te de l'architecture tissulaire et des interactions cellule鈥揷ellule sans n茅cessiter de proc茅dures complexes de cor茅gistration des donn茅es.
10x Genomics (Nasdaq: TXG) hat Xenium Protein eingef眉hrt, eine innovative Erg盲nzung zur Xenium Spatial-Plattform, die die gleichzeitige Detektion von RNA und Proteinen in derselben Zelle und Gewebeschnitt in einem einzigen automatisierten Lauf erm枚glicht. Dieser Durchbruch stellt den ersten vollst盲ndig integrierten r盲umlichen Multiomik-Workflow f眉r die Xenium-Plattform dar.
Das neue Produkt bietet gebrauchsfertige Protein-Subpanels, die neben RNA-Panels eingesetzt werden und dutzende Proteine abdecken, die an Zellwachstum, Signal眉bertragung und Immunantwort beteiligt sind. Die Technologie vereinfacht Forschungsabl盲ufe, da separate Technologien oder Probenabschnitte entfallen 鈥� besonders vorteilhaft f眉r die Untersuchung von Krebs, Immunologie und komplexen Erkrankungen.
Die fr眉he Einf眉hrung durch Unternehmen wie Sanofi zeigt den Nutzen der Plattform bei der umfassenden Analyse der Gewebe-Architektur und der Zell-Zell-Interaktionen, ohne aufw盲ndige Daten-Koregistrierung zu erfordern.
- First fully integrated spatial multiomic workflow enabling simultaneous RNA and protein detection
- Streamlines research process by eliminating need for multiple technologies and complex data integration
- Ready-to-use protein subpanels work seamlessly with existing RNA panels
- Early adoption by major pharmaceutical companies like Sanofi
- None.
Insights
10x Genomics' Xenium Protein launch significantly advances spatial biology capabilities, strengthening their competitive position in the fast-growing multiomic analysis market.
10x Genomics has made a significant technological advancement with the launch of Xenium Protein, expanding their spatial biology platform to enable simultaneous RNA and protein detection within the same cells and tissue sections in a single automated run. This represents a major leap forward in spatial multiomics - a rapidly growing field essential for understanding complex diseases at the cellular level.
The strategic importance of this launch cannot be overstated. By integrating RNA and protein analysis in one workflow, 10x eliminates the need for researchers to use multiple technologies or complex data integration methods. This translates to faster experiment-to-insight timelines and more precise biological understanding - critical factors for researchers studying cancer, immunology, and other disease areas.
What makes this particularly valuable is the reduction in technical variables that typically arise when combining data from different platforms. As Sanofi's Dr. Tessier noted, this integrated approach removes reliance on data co-registration, which often introduces uncertainty into research results. For pharmaceutical companies and research institutions, this means higher confidence in findings that drive therapeutic development decisions.
The global availability announcement indicates 10x has overcome manufacturing and distribution challenges for this complex product. The ready-to-use protein subpanels focused on cell growth, signaling, and immune response are strategically aligned with high-value research areas that typically command significant research funding. Early adoption by Sanofi, a major pharmaceutical company, signals strong potential for market acceptance among enterprise-level customers with substantial research budgets.
First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ 鈥� unlocking deeper insights into cell function and disease biology
"Scientists can now analyze RNA and protein together, streamlining workflows, removing the need for complex data integration and unlocking more precise insights," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "Integrated multiomic analysis is essential to advancing our understanding of complex diseases and accelerating therapeutic discovery."
Xenium Protein expands the Xenium platform with ready-to-use protein subpanels that work seamlessly alongside RNA panels, all on the same slide. These initial subpanels include dozens of well-characterized proteins involved in cell growth, signaling and immune response 鈥� making them valuable for studying cancer, immunology and other complex disease areas.
By reducing the need for separate workflows, technologies or sample sections, Xenium Protein simplifies experimental design and shortens time to results. With both RNA and protein data captured in a single run, researchers can move more quickly from experiment to insight 鈥� accelerating the pace of valuable discoveries possible through multiomic analysis.
Early access customers are leveraging Xenium Protein from early discovery through translational research and large-scale atlasing efforts.
"Integrating RNA and protein analysis within the same Xenium workflow enables a comprehensive view of tissue architecture and cell-cell interactions in a single experiment," said Dr. Julien Tessier, Principal Scientist, Sanofi. "This integrated multiomics approach removes the reliance on data co-registration 鈥� which is often complex and can introduce uncertainty 鈥� while delivering critical insights into target and biomarker expression that RNA alone often fails to capture."
Xenium Protein is now available globally.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Contacts
Investors: [email protected]
Media: [email protected]
View original content to download multimedia:
SOURCE 10x Genomics, Inc.
FAQ
What is the new Xenium Protein product launched by 10x Genomics (TXG)?
How does Xenium Protein benefit researchers compared to existing methods?
What applications is the TXG Xenium Protein platform designed for?
When will Xenium Protein be available to researchers?
What are the key features of 10x Genomics' Xenium Protein platform?
